Ensysce Biosciences said this week that its extended-release oxycodone prodrug won fast track status from the FDA.
The San Diego, Calif.-based company is developing the abuse-deterrent drug as a pain management therapy for people with moderate to severe chronic pain.
Get the full story at our sister site, Drug Delivery Business News.
The post Ensysce Bioscience wins fast track status for abuse-deterrent oxycodone appeared first on MassDevice.